Eli Lilly has filed lawsuits against six U.S. entities it accuses of selling black market versions of its experimental weight loss drug retatrutide, a GLP-1 medication still in late-stage clinical trials. The suits target compounding pharmacies, medical spas, and online sellers that market the drug as a weight-loss “hack,” according to court filings in California and Texas.
The defendants—Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide—allegedly label the product as “research-use only” while actually intending it for human consumption. Lilly contends this is a deliberate attempt to exploit a regulatory loophole that permits the sale of unapproved compounds for experimental purposes, but the drugs are often manufactured by unregulated foreign facilities with no FDA oversight and unverified ingredients.
Retatrutide has not been approved by any regulatory agency worldwide, and the FDA has explicitly stated that it cannot be legally compounded or sold. Lilly plans to submit the drug to the FDA for approval by the end of the year, and studies suggest it may be more effective than existing GLP-1 treatments. The company warns that black market versions pose significant health risks, as their contents and production standards are unverified.
“Retatrutide is being rigorously studied as part of a comprehensive clinical trial development program,” said Dr. David A. Hyman, Lilly’s chief medical officer. “We take the responsibility of evaluating the safety and efficacy of our investigational medicines seriously. What is being sold on the black market is not a medicine—it is entirely unverified, unapproved and not worth the risk.”
Beyond the lawsuits, Lilly has referred more than 200 individuals and entities to the FDA, the U.S. Department of Justice, state attorneys general, law enforcement, and professional licensing boards. The company is also coordinating with global regulators and customs authorities to disrupt the illegal supply chain. Lilly is urging e-commerce platforms and social media companies to take proactive steps to block such sales, rather than enabling or fueling them.
The crackdown comes as the market for compounded GLP-1 drugs expands, with companies like Hims & Hers moving into the compounded peptides space. The FDA has warned that unapproved versions of these drugs can be dangerous, and Lilly’s legal actions underscore the regulatory and safety concerns surrounding the gray market.
Legal experts say the outcome of these cases could set a precedent for how pharmaceutical companies protect their investigational products from unauthorized sales. The lawsuits also highlight the tension between the growing demand for weight loss treatments and the strict regulatory framework governing drug approval.
Lilly’s move is part of a broader industry effort to combat counterfeit and unapproved versions of GLP-1 drugs, which have become blockbuster therapies. As the company prepares to seek FDA approval for retatrutide, it is simultaneously working to ensure that only safe, regulated versions reach patients.
